Nevertheless, an anti-CCR2 antibody (MLN1202) tested in a phase II clinical trial for metastatic cancer showed therapeutic effects in 14 out of 43 patients with bone metastases (ClinicalTrials.gov ID: NCT01015560). The gene discussed is CCR2; the disease is metastatic malignant neoplasm.